Meet Our Leadership Team
PathoQuest’s management team has significant experience and expertise in the development, implementation, and commercialization of genomic and bioinformatic solutions for the identification of pathogens and in vitro diagnostics.
Jean-Francois Brepson - President and CEO
Jean-François Brepson has over 20 years leadership experience in the Pharmaceutical Industry. Prior to joining PathoQuest, Mr. Brepson was a Senior Vice-President at IPSEN where he was responsible for leading the global GI-Oncology & Endocrinology Franchise. He made a decisive contribution to the creation of leading portfolio in Neuro-Endocrine Tumors in close collaboration with R&D and Business Development teams. He led the pre-launch of IPSEN first product in GI-Oncology on a worldwide basis. Prior to this, Mr. Brepson held several commercial operations positions at IPSEN including area Manager, BU Head, and General Manager in the EMEA region. Mr. Brepson has an Engineering Degree in Data Management System and a Master Degree in Foreign Trade. He has also earned “The Leadership & Innovation Certificate” for HEC in Paris and “The Blue Ocean Strategy Certificate” from INSEAD in Fontainebleau.
Helene Peyro-Saint-Paul, M.D., M.B.A. - Chief Medical Officer
Dr. Hélène Peyro-Saint-Paul has held a number of executive positions in the life sciences industry and has contributed to the development and launch of several innovative molecules. Prior to joining PathoQuest, Dr. Peyro-Saint-Paul served as Chief Medical Officer of Ipsogen SA. Dr. Peyro-Saint-Paul was also previously Founder and Vice President of Medical and Corporate Affairs at HalioDx SAS. Prior to this she served as European Medical Affairs Director, then Global Strategic Marketing Director for metabolic diseases at Actelion. As International Medical Affairs Director at Serono, Dr. Peyro-Saint-Paul contributed to the launch and reimbursement of Rebif, a reference treatment for multiple sclerosis, in Europe and the United States. Since joining the pharmaceutical industry, she developed her expertise in pharmaco-economics. Dr Peyro-Saint-Paul holds a doctorate in Medicine (Neurology) from Toulouse University, and a degree in Molecular Genetics. She received an Executive MBA from ESSEC in 2000.
Pascale Beurdeley, Ph.D. - Chief Scientific Officer
Dr. Pascale Beurdeley has 18 years experience in the biotechnology industry. Prior to joining PathoQuest, Dr. Beurdeley held several positions at DiaxonHit (formerly ExonHit Therapeutics) with increasing responsibilities from Group Leader R&D to Executive Director R&D, Genomics where she contributed to the development and the promotion of the company’s proprietary platform for the analysis of gene expression and alternative splicing. Dr. Beurdeley was also in charge of the implementation and the management of innovative R&D projects for both internal and collaborative programs in oncology and Alzheimer’s disease. She also acquired significant expertise in the conception and development of innovative diagnostic products in compliance with regulatory requirements. Prior to joining ExonHit Therapeutics, Dr. Beurdeley held a researcher position in the translational medicine department at the Curie Institute. Dr. Beurdeley is graduated from the University Louis Pasteur (Strasbourg) and holds a Ph.D in Molecular and Cell Biology. She completed her training as a post-doctoral fellow at Magainin Pharmaceuticals Inc, focusing on her interest in antimicrobial peptides.
Charles Hébert, Ph.D. - Chief Technology Information Officer
Dr. Charles Hébert has expertise in knowledge management, machine learning, data mining, statistics, genomic and transcriptomic analyses, and high throughput next generation sequencing. Dr. Hébert has a Ph.D.in Bioinformatics from Ecole normale supérieure and a Master in Bioinformatics from the Université Denis Diderot (Paris VII).
Jean-Marie Charpin, Ph.D. - Global Commercial Head, Bioproduction Safety
Jean-Marie Charpin has been leading sales and business development internationally for 16 years in CRO businesses to the Pharma and Biotech Industry. Prior to joining PathoQuest, Dr. Charpin was Business Account Manager and Product Manager at OncoDesign. He developed the business in north Europe and successfully launch innovative services (Patient Derived Xenograft) for preclinical Oncology worldwide. Prior to this, he was leading the sales team in France for SGS GMP Laboratory services in analytical chemistry and microbiology. As Sales Manager at Texcell, he developed the biosafety and Immunology business through North Europe and coordinated the Indian Distributor. Since joining the CRO business, he developed his knowledge of the regulatory requirements (particularly in viral safety, QC testing and preclinical development) and showed a customer oriented mindset. Mr Charpin holds a PhD in Medical Biology with a focus on pulmonary Immunology from Faculty of Medicine Necker-Enfants Malades, University of Paris Descartes.
Marc Eloit, DVM, PhD - Founder and Scientific Advisor
Prof. Marc Eloit, DVM, PhD is the Founder of PathoQuest. Dr. Eloit is a Professor of Virology and the former head of the Virology Unit at the Veterinary School of Maisons-Alfort. He joined the Institut Pasteur in 2008 to develop a program of Pathogen Discovery based on Next Generation Sequencing (NGS). Dr. Eloit received his DVM from the Veterinary School of Maisons-Alfort and his PhD from University Paris VI.